Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression

Toxicology and Applied Pharmacology

Volumn 280, Issue 1, 2014, Pages 138-148

  Do, Minh Truong ^a   Kim, Hyung Gyun ^a   Tran, Thi Thu Phuong ^a   Khanal, Tilak ^a   Choi, Jae Ho ^a   Chung, Young Chul ^b   Jeong, Tae Cheon ^c   Jeong, Hye Gwang ^a  

^a Chungnam National University   (South Korea)

^b International University of Korea   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

AhR; CYP1A1; CYP1B1; Metformin; Sp1

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR; LIGAND; MESSENGER RNA; METFORMIN; TRANSCRIPTION FACTOR SP1; TRYPTOPHAN 2,3 DIOXYGENASE; CYP1A1 PROTEIN, HUMAN; CYP1B1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DOWN REGULATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; BREAST CARCINOGENESIS; CANCER RISK; CHEMOPROPHYLAXIS; GENE REPRESSION;

BREAST NEOPLASMS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1B1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; METFORMIN; RECEPTORS, ARYL HYDROCARBON;

EID: 84906517473     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.07.021     Document Type: Article

References (46)

1. Alimova I.N., Liu B., Fan Z., Edgerton S.M., Dillon T., Lind S.E., Thor A.D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915.
2. Androutsopoulos V.P., Tsatsakis A.M., Spandidos D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 2009, 9:187.
3. Beedanagari S.R., Bebenek I., Bui P., Hankinson O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol. Sci. 2009, 110:61-67.
4. Bodmer M., Meier C., Krahenbuhl S., Jick S.S., Meier C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33:1304-1308.
5. Bottner M., Christoffel J., Jarry H., Wuttke W. Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on pituitary function in rats. J. Endocrinol. 2006, 189:77-88.
6. Casper R.F., Quesne M., Rogers I.M., Shirota T., Jolivet A., Milgrom E., Savouret J.F. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 1999, 56:784-790.
7. Castro-Rivera E., Samudio I., Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem. 2001, 276:30853-30861.
8. Choi H., Chun Y.S., Shin Y.J., Ye S.K., Kim M.S., Park J.W. Curcumin attenuates cytochrome P450 induction in response to 2,3,7,8-tetrachlorodibenzo-p-dioxin by ROS-dependently degrading AhR and ARNT. Cancer Sci. 2008, 99:2518-2524.
9. Chuang C.W., Pan M.R., Hou M.F., Hung W.C. Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells. J. Cell. Physiol. 2013, 228:341-348.
10. Dallaglio K., Bruno A., Cantelmo A.R., Esposito A.I., Ruggiero L., Orecchioni S., Calleri A., Bertolini F., Pfeffer U., Noonan D.M., Albini A. Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis 2014, 35:1055-1066.
11. Dietrich C., Kaina B. The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 2010, 31:1319-1328.
12. DiNatale B.C., Murray I.A., Schroeder J.C., Flaveny C.A., Lahoti T.S., Laurenzana E.M., Omiecinski C.J., Perdew G.H. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 2010, 115:89-97.
13. Do M.T., Kim H.G., Khanal T., Choi J.H., Kim D.H., Jeong T.C., Jeong H.G. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicol. Appl. Pharmacol. 2013, 271:229-238.
14. Feng S., Cao Z., Wang X. Role of aryl hydrocarbon receptor in cancer. Biochim. Biophys. Acta 2013, 1836:197-210.
15. Goode G.D., Ballard B.R., Manning H.C., Freeman M.L., Kang Y., Eltom S.E. Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line. Int. J. Cancer 2013, 133:2769-2780.
16. Gramatzki D., Pantazis G., Schittenhelm J., Tabatabai G., Kohle C., Wick W., Schwarz M., Weller M., Tritschler I. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene 2009, 28:2593-2605.
17. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
18. Kadonaga J.T., Courey A.J., Ladika J., Tjian R. Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science 1988, 242:1566-1570.
19. Kolla V., Litwack G. Upregulation of mineralocorticoid- and glucocorticoid-receptor gene expression by Sp-I. Mol. Cell. Biol. Res. Commun. 1999, 1:44-47.
20. Lai S.W., Chen P.C., Liao K.F., Muo C.H., Lin C.C., Sung F.C. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am. J. Gastroenterol. 2012, 107:46-52.
21. Larsen M.C., Angus W.G., Brake P.B., Eltom S.E., Sukow K.A., Jefcoate C.R. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res. 1998, 58:2366-2374.
22. Li D., Yeung S.C., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
23. Lob S., Konigsrainer A., Rammensee H.G., Opelz G., Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat. Rev. Cancer 2009, 9:445-452.
24. Maayah Z.H., AlHaider A.A., Korashy H.M. Chemopreventive role of metformin during DMBA-induced breast carcinogenesis in MCF10A cells through CYP1A1-AhR signaling pathway. FASEB J. 2013, 27:1104.3.
25. Miller D.M., Polansky D.A., Thomas S.D., Ray R., Campbell V.W., Sanchez J., Koller C.A. Mithramycin selectively inhibits transcription of G-C containing DNA. Am. J. Med. Sci. 1987, 294:388-394.
26. Mireuta M., Darnel A., Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 2010, 28:243-255.
27. Moennikes O., Loeppen S., Buchmann A., Andersson P., Ittrich C., Poellinger L., Schwarz M. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 2004, 64:4707-4710.
28. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11:312-319.
29. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol. Med. 2004, 10:15-18.
30. Nair V., Pathi S., Jutooru I., Sreevalsan S., Basha R., Abdelrahim M., Samudio I., Safe S. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 2013, 34:2870-2879.
31. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., Schumacher T., Jestaedt L., Schrenk D., Weller M., Jugold M., Guillemin G.J., Miller C.L., Lutz C., Radlwimmer B., Lehmann I., von Deimling A., Wick W., Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
32. Pilotte L., Larrieu P., Stroobant V., Colau D., Dolusic E., Frederick R., De Plaen E., Uyttenhove C., Wouters J., Masereel B., Van den Eynde B.J. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2497-2502.
33. Racky J., Schmitz H.J., Kauffmann H.M., Schrenk D. Single nucleotide polymorphism analysis and functional characterization of the human Ah receptor (AhR) gene promoter. Arch. Biochem. Biophys. 2004, 421:91-98.
34. Rodriguez M., Potter D.A. CYP1A1 regulates breast cancer proliferation and survival. Mol. Cancer Res. 2013, 11:780-792.
35. Rogatsky I., Waase C.L., Garabedian M.J. Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3). Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J. Biol. Chem. 1998, 273:14315-14321.
36. Safe S., Lee S.O., Jin U.H. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol. Sci. 2013, 135:1-16.
37. Sastry M., Patel D.J. Solution structure of the mithramycin dimer-DNA complex. Biochemistry 1993, 32:6588-6604.
38. Soichot M., Vaast A., Vignau J., Guillemin G.J., Lhermitte M., Broly F., Allorge D. Characterization of functional polymorphisms and glucocorticoid-responsive elements in the promoter of TDO2, a candidate gene for ethanol-induced behavioural disorders. Alcohol Alcohol. 2013, 48:415-425.
39. Stoner M., Wormke M., Saville B., Samudio I., Qin C., Abdelrahim M., Safe S. Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins. Oncogene 2004, 23:1052-1063.
40. Suehiro T., Kaneda T., Ikeda Y., Arii K., Kumon Y., Hashimoto K. Regulation of human glucocorticoid receptor gene transcription by Sp1 and p53. Mol. Cell. Endocrinol. 2004, 222:33-40.
41. Tsuchiya Y., Nakajima M., Yokoi T. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J. Biochem. 2003, 133:583-592.
42. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
43. Vinothini G., Nagini S. Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFkappaB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast. Clin. Chim. Acta 2010, 411:368-374.
44. Wright J.L., Stanford J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009, 20:1617-1622.
45. Yager J.D. Catechol-methyltransferase: characteristics, polymorphisms and role in breast cancer. Drug Discov. Today Dis. Mech. 2012, 9:e41-e46.
46. Zudaire E., Cuesta N., Murty V., Woodson K., Adams L., Gonzalez N., Martinez A., Narayan G., Kirsch I., Franklin W., Hirsch F., Birrer M., Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J. Clin. Invest. 2008, 118:640-650.